CYDY - Equillium Jumps On Data And Other News: The Good Bad And Ugly Of Biopharma
Equillium stock jumps on encouraging Itolizumab interim data
Equillium Inc. (EQ) reported positive interim data for its lead drug candidate Itolizumab from the first two cohorts of the Phase 1b trial. The drug candidate was found to be generally well-tolerated and five out of seven patients demonstrated a complete response by Day 29.
The EQUATE study is a Phase 1b/2 trial. It aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity of itolizumab as a first-line treatment in patients who present with aGVHD. The Phase 1b part of the study is